Posted by Michael Wonder on 07 Jun 2023
PHARMAC confirms funding of rituximab for IgG4 related disease
7 June 2023 - PHARMAC has published a notification for widened access to rituximab (Riximyo) for people with the chronic inflammatory condition immunoglobulin G4-related disease (IgG4-RD).
PHARMAC currently funds rituximab for cancer, rheumatoid arthritis, and auto-immune and blood conditions.
